Whitehawk Therapeutics, Inc.
WHWKHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Whitehawk Therapeutics, Inc. focuses on Biotechnology services and products. Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. Valued at $183.0M, WHWK is a micro-cap name in its sector. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Market Cap
$183.0M
Beta
0.91
P/E (TTM)
—
P/E (Fwd)
-3.25
EPS (TTM)
$-1.13
EPS (Fwd)
$-0.99
ROE
-45.0%
ROA
-28.7%
Cash
$190.0M
Total Debt
$0
Free CF
-$43.6M
52W Change
32.6%
Annual Financials
Cash vs Debt
Where WHWK stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, WHWK finished 26.04% below its 150-day moving average ($4.07) and 21.00% below its 200-day moving average ($3.81). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is WHWK overbought or oversold?
At the October 20, 2026 close, WHWK's RSI(14) was 23.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Whitehawk Therapeutics, Inc. reports $190.0M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$43.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -45.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $15.2M to $7.1M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing WHWK.